Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.78B |
| 2 |
Microsoft
MSFT
|
+$2.22B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.67B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.65B |
| 5 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.19B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.45B |
| 2 |
iShares US Real Estate ETF
IYR
|
+$533M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$410M |
| 4 |
Stellantis
STLA
|
+$312M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$240M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.28% |
| 2 | Healthcare | 11.27% |
| 3 | Financials | 10.52% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3676
Amplify Energy
AMPY
$161M
| $48.9K | ﹤0.01% |
7,223
-10,814
| -60% | -$75.3K |
|
|
DNMR
3677
DELISTED
Danimer Scientific, Inc.
DNMR
| $48.9K | ﹤0.01% |
514
-639
| -55% | -$82K |
|
3678
Forafric Global
AFRI
$289M
| $48.8K | ﹤0.01% |
+4,448
| New | +$48.9K |
|
3679
SKYX Platforms
SKYX
$147M
| $48.7K | ﹤0.01% |
+18,300
| New | +$58.8K |
|
3680
iShares MSCI USA Momentum Factor ETF
MTUM
$25B
| $48.6K | ﹤0.01% |
337
-29,487
| -99% | -$4.15M |
|
3681
Savara
SVRA
$1.12B
| $48.6K | ﹤0.01% |
15,215
-9,338
| -38% | -$21.9K |
|
3682
VanEck Morningstar Wide Moat ETF
MOAT
$11.9B
| $48.4K | ﹤0.01% |
+606
| New | +$45.6K |
|
3683
Olema Pharmaceuticals
OLMA
$1B
| $48.3K | ﹤0.01% |
5,352
+730
| +16% | +$4.41K |
|
|
OSG
3684
DELISTED
Overseas Shipholding Group Inc.
OSG
| $48.2K | ﹤0.01% |
11,566
-23,090
| -67% | -$89.2K |
|
3685
State Street SPDR S&P Kensho Smart Mobility ETF
HAIL
$18.9M
| $47.8K | ﹤0.01% |
1,430
| – | – |
|
3686
Primis Financial Corp
FRST
$399M
| $47.8K | ﹤0.01% |
5,675
-5,400
| -49% | -$45.2K |
|
3687
Q32 Bio
QTTB
$466M
| $47.5K | ﹤0.01% |
2,983
| – | – |
|
3688
Tyra Biosciences
TYRA
$1.9B
| $47.5K | ﹤0.01% |
2,788
-3,997
| -59% | -$58K |
|
3689
Ubiquiti
UI
$33.7B
| $47.5K | ﹤0.01% |
270
-51
| -16% | -$10.3K |
|
3690
Oramed Pharmaceuticals
ORMP
$167M
| $47.4K | ﹤0.01% |
13,239
-7,410
| -36% | -$23.8K |
|
3691
Mineralys Therapeutics
MLYS
$2.25B
| $47.4K | ﹤0.01% |
2,778
-9,758
| -78% | -$146K |
|
3692
Cue Biopharma
CUE
$113M
| $47.3K | ﹤0.01% |
432
+231
| +115% | +$27.1K |
|
3693
OptimizeRx
OPRX
$114M
| $47.2K | ﹤0.01% |
3,305
-5,137
| -61% | -$73.2K |
|
3694
Red River Bancshares
RRBI
$662M
| $47.2K | ﹤0.01% |
961
-1,245
| -56% | -$60.8K |
|
3695
Spok Holdings
SPOK
$228M
| $47.2K | ﹤0.01% |
3,552
-59,095
| -94% | -$741K |
|
3696
Structure Therapeutics
GPCR
$3.41B
| $47.1K | ﹤0.01% |
+1,132
| New | +$31.7K |
|
3697
Angi Inc
ANGI
$229M
| $46.9K | ﹤0.01% |
1,421
+1,416
| +28,320% | +$39.6K |
|
3698
American Express Global Business Travel
GBTG
$4.93B
| $46.7K | ﹤0.01% |
+6,464
| New | +$44K |
|
|
CARM
3699
DELISTED
Carisma Therapeutics
CARM
| $46.6K | ﹤0.01% |
+5,312
| New | +$28.9K |
|
3700
Asure Software
ASUR
$232M
| $46.6K | ﹤0.01% |
3,830
-22,427
| -85% | -$299K |
|
Similar funds
Barclays's Q2 2023 Portfolio in Review
As of Q2 2023, Barclays held 5,371 positions worth $158B, down 28% from $218B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays withdrew a net $70.1B in Q2 2023, closing 872 positions and reducing 1,669 holdings. Its most notable exit was DCP Midstream, LP, an estimated $47.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 12% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Barclays opened a new position in State Street SPDR Nuveen ICE Municipal Bond ETF worth $36.9M.
- Barclays's largest Q2 2023 buy was State Street SPDR Nuveen ICE Municipal Bond ETF: 799,988 shares worth $36.9M.
- Barclays added most to Apple in Q2 2023, an estimated $2.78B increase.
- Barclays's biggest Q2 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.45B.
- Barclays fully exited DCP Midstream, LP in Q2 2023, selling an estimated $47.3M.
- Barclays's ten largest holdings make up 24% of its $158B portfolio in Q2 2023.
- Barclays opened 314 new positions and closed 872 in Q2 2023.
- Barclays's portfolio value fell 28% quarter-over-quarter to $158B.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.